JACC. Case reports · 2025
First Post-Approval Clinical Use of F-18 Flurpiridaz With Exercise Cardiac PET in the United States.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tandon Suman, Khalique Omar K, Chen Lu Q
Аннотация
BACKGROUND: F-18 flurpiridaz is a novel radiotracer approved for positron emission tmography (PET) myocardial perfusion imaging. Its long half-life supports exercise stress testing, and its short positron range and high myocardial extraction fraction provide superior image resolution.
EARLY REPORTS SUMMARY: A 70-year-old man with known coronary artery disease and prior coronary revascularization underwent exercise cardiac PET with F-18 flurpiridaz for chest discomfort. PET showed ischemia in the left anterior descending and right coronary artery territories. Coronary angiography revealed a severe mid-left anterior descending lesion and a severe proximal lesion in a small-caliber right posterior descending artery.
DISCUSSION: Ischemia on PET correlated with coronary angiography and optical coherence tomography, guiding revascularization and altering clinical management.
NOVELTY: This case represents the first post-approval clinical experience of F-18 flurpiridaz with exercise cardiac PET imaging in the United States.
TAKE-HOME MESSAGE: F-18 flurpiridaz has made exercise cardiac PET feasible in the clinical setting.
EARLY REPORTS SUMMARY: A 70-year-old man with known coronary artery disease and prior coronary revascularization underwent exercise cardiac PET with F-18 flurpiridaz for chest discomfort. PET showed ischemia in the left anterior descending and right coronary artery territories. Coronary angiography revealed a severe mid-left anterior descending lesion and a severe proximal lesion in a small-caliber right posterior descending artery.
DISCUSSION: Ischemia on PET correlated with coronary angiography and optical coherence tomography, guiding revascularization and altering clinical management.
NOVELTY: This case represents the first post-approval clinical experience of F-18 flurpiridaz with exercise cardiac PET imaging in the United States.
TAKE-HOME MESSAGE: F-18 flurpiridaz has made exercise cardiac PET feasible in the clinical setting.